Cytosorbents (CTSO) Cash & Equivalents Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -13.31% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 34.27% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 8.10% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 8.16% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 40.74% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -2.57% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 2.72% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 38.28% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 32.23% |
| 10 | Cytosorbents | 23.26 Mn | 18.85 Mn | 7.05 Mn | -30.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.60% |
| Mar 31, 2026 | -36.84% |
| Dec 31, 2025 | -34.41% |
| Sep 30, 2025 | -30.61% |
| Jun 30, 2025 | -30.32% |
| Mar 31, 2025 | -32.71% |
| Dec 31, 2024 | -42.79% |
| Sep 30, 2024 | -52.60% |
| Jun 30, 2024 | -49.48% |
| Mar 31, 2024 | -49.90% |
| Dec 31, 2023 | -41.73% |
| Sep 30, 2023 | -54.37% |
| Jun 30, 2023 | -27.92% |
| Mar 31, 2023 | -10.30% |
| Dec 31, 2022 | 21.88% |
| Sep 30, 2022 | 12.17% |
| Jun 30, 2022 | 22.67% |
| Mar 31, 2022 | 29.86% |
| Dec 31, 2021 | 32.59% |
| Sep 30, 2021 | 34.82% |